Abstract:Unique lindenane sesquiterpenoid dimers from Chloranthecae spp. were recently identified with promising in vitro antiplasmodial activity and potentially novel mechanisms of action. To gain mechanistic insights to this new class of natural products, in vitro selection of Plasmodium falciparum resistance to the most active antiplasmodial compound, chlorajaponilide C, was explored. In all selected resistant clones, the half-maximal effective concentration (EC50) of chlorajaponilide C increased >250-fold, and whole genome sequencing revealed mutations in the recently discovered P. falciparum prodrug activation and resistance esterase (PfPARE). Chlorajaponilide C was highly potent (mean EC50 = 1.6 nM, n = 34) against fresh Ugandan P. falciparum isolates. The analysis of the structure-resistance relationships revealed that in vitro potency of a subset of lindenane sesquiterpenoid dimers was not mediated by PfPARE mutations. Thus, chlorajaponilide C, but not some related compounds, required parasite esterase activity for in vitro potency, and those compounds serve as the foundation for development of potent and selective antimalarials.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsinfecdis.0c00487?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00487</a>.Dose response curves for chlorajaponilide C in 3D7-WT and Dd2 strains and EC50 values of chlorajaponilide C in 3D7-R1 after 3 months without drug pressure (Figure S1); amino acid sequence alignment for Pf3D7_0709700 (PlasmoDB), 3D7-WT, and 3D7-R1–4 strains (Figure S2); Western blot showing expression of WT-PARE in the 3D7-R1 strain (Figure S3); dose response curves for fortunilide G in 3D7-WT and P. falciparum resistant strains (Figure S4); purity of lindenane sesquiterpenoid dimers (Table S1) (<a class="ext-link" href="/doi/suppl/10.1021/acsinfecdis.0c00487/suppl_file/id0c00487_si_001.pdf">PDF</a>)All genomic variants identified in each of the individual strains compared to the 3D7 reference strain in PlasmoDB as well as the identified genomic variants in the resistant clones with respect to 3D7-WT (Table S2) (<a class="ext-link" href="/doi/suppl/10.1021/acsinfecdis.0c00487/suppl_file/id0c00487_si_002.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Tartrolon E, a secondary metabolite of a marine symbiotic bacterium, is a potent inhibitor of asexual and sexual Plasmodium falciparum

Novel quinolinepiperazinyl-aryltetrazoles targeting the blood stage of Plasmodium falciparum

A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo

Isolation and In Vitro and In Vivo Activity of Secondary Metabolites from Clerodendrum polycephalum Baker against Plasmodium Malaria Parasites

Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

Inhibition of Plasmodium falciparum Lysyl-tRNA synthetase via an anaplastic lymphoma kinase inhibitor

High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of Plasmodium falciparum

A novel multiple-stage antimalarial agent that inhibits protein synthesis

Assessment In Vitro of the Antimalarial and Transmission-Blocking Activities of Cipargamin and Ganaplacide in Artemisinin-Resistant Plasmodium falciparum

Poly-basic peptides and polymers as new drug candidates against Plasmodium falciparum

An Allosteric Inhibitory Potential of Triterpenes from Combretum racemosum on the Structural and Functional Dynamics of Plasmodium falciparum Lactate Dehydrogenase Binding Landscape

Dietary Flavonoids Fisetin and Myricetin: Dual Inhibitors of Plasmodium Falciparum Falcipain-2 and Plasmepsin II.

Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1

Poly-basic peptides and polymers as new drug candidate against Plasmodium falciparum

A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants

Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a Plasmodium falciparum Esterase

Exploring Novel Antimalarial Compounds Targeting Plasmodium falciparum Enoyl-ACP Reductase: Computational and Experimental Insights

Mutation in the 26S proteasome regulatory subunit rpn2 gene in Plasmodium falciparum confers resistance to artemisinin

Blocking Plasmodium falciparum Development via Dual Inhibition of Hemoglobin Degradation and the Ubiquitin Proteasome System by MG132

Target-Based Virtual Screening of Natural Compounds Identifies a Potent Antimalarial With Selective Falcipain-2 Inhibitory Activity